Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Jagsonpal Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Jagsonpal Pharmaceuticals has a total shareholder equity of ₹1.9B and total debt of ₹89.4M, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are ₹2.2B and ₹296.8M respectively. Jagsonpal Pharmaceuticals's EBIT is ₹223.3M making its interest coverage ratio 25.4. It has cash and short-term investments of ₹1.5B.
Anahtar bilgiler
4.8%
Borç/özkaynak oranı
₹89.41m
Borç
| Faiz karşılama oranı | 25.4x |
| Nakit | ₹1.48b |
| Eşitlik | ₹1.87b |
| Toplam yükümlülükler | ₹296.76m |
| Toplam varlıklar | ₹2.17b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings
May 27
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: JAGSNPHARM's short term assets (₹2.0B) exceed its short term liabilities (₹191.3M).
Uzun Vadeli Yükümlülükler: JAGSNPHARM's short term assets (₹2.0B) exceed its long term liabilities (₹105.5M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: JAGSNPHARM has more cash than its total debt.
Borcun Azaltılması: JAGSNPHARM's debt to equity ratio has increased from 3.6% to 4.8% over the past 5 years.
Borç Kapsamı: JAGSNPHARM's debt is well covered by operating cash flow (393.3%).
Faiz Kapsamı: JAGSNPHARM's interest payments on its debt are well covered by EBIT (25.4x coverage).